Matrix Laboratories, a Hyderabad-based subsidiary of Mylan Inc. has received tentative approval from the US FDA under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for efavirenz, lamivudine and tenofovir disoproxil fumarate tablets, 600 mg/300 mg/300 mg.
The details can be read here.
No comments:
Post a Comment